Thanks TheDhon,
Hope we can see the announcement from NSAID pain program soon.
"Significant upside from NSAID pain program - Imugene currently have Phase I clinical data for naproxen (branded in Australia as Naprosyn) and ibuprofen (branded in Australia as Nurofen) and are initiating formulation development for diclofenac (branded in Australian as Voltaren). If successful, even a small share of the NSAID market (<0.5%) would represent an opportunity of $50M-$100M in annual sales (assume single digit royalties to Imugene)."
current 2m MC vs $50m-100m potential annual sales......imaging that.
If this program is successful, IMU is worth 50c-$1.00 per share.
If only $5m not $50m, SP should also well above 10c.
10c target in 12 month , page-17
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $279.2K | 5.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 94 | 12992150 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1795056 | 6 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |